In the claims:

1. (Original) A compound of Formula I



I

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X is O, S or NR^3;

m is 0, 1, 2 or 3;

n is 0, 1, 2 or 3;

R^1 is:

1) H,
2) $O_r(C_1\text{-}C_6)$perfluoroalkyl,
3) OH,
4) CN,
5) halogen,
6) $(C{=}O)_rO_s(C_1\text{-}C_{10})$alkyl,
7) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkenyl,
8) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkynyl,
9) $(C{=}O)_rO_s$aryl,
10) $(C{=}O)_rO_s$heterocyclyl, or
11) $(C_0\text{-}C_6)$alkyl-NR^aR^b,

wherein r and s are independently 0 or 1, and said alkyl, alkenyl, alkynyl, aryl and heterocyclyl is optionally substituted with one or more substituents selected from R^6;

R^2 is:

1) H,
2) $O_r(C_1\text{-}C_6)$perfluoroalkyl,
3) OH,
4) CN,
5) halogen,
6) $(C{=}O)_rO_s(C_1\text{-}C_{10})$alkyl,
7) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkenyl,
8) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkynyl,
9) $(C{=}O)_rO_s$aryl,
10) $(C{=}O)_rO_s$heterocyclyl, or
11) $(C_0\text{-}C_6)$alkyl-NR^aR^b,

wherein r and s are independently 0 or 1, and said alkyl, alkenyl, alkynyl, aryl and heterocyclyl is optionally substituted with one or more substituents selected from R^6;

R^3 is:

1) H,
2) SO_2R^c,
3) $(C{=}O)_rR^c$, wherein r is 0 or 1, or
4) CO_2R^c;

R^4 is:

1) H,
2) $O_r(C_1\text{-}C_6)$perfluoroalkyl,
3) OH,
4) CN,
5) halogen,
6) $(C{=}O)_rO_s(C_1\text{-}C_{10})$alkyl,
7) $(C{=}O)_rO_s(C_2\text{-}C_{10})$alkenyl,

8) $(C=O)_rO_s(C_2\text{-}C_{10})$alkynyl,
9) $(C=O)_rO_s$aryl,
10) $(C=O)_rO_s$heterocyclyl, or
11) $(C_0\text{-}C_6)$alkyl-NR^aR^b,

wherein r and s are independently 0 or 1, and said alky, alkenyl, alkynyl, aryl and heterocyclyl is optionally substituted with one or more substituents selected from R^6;

R^5 is heterocyclyl wherein said heterocyclyl contains one or two additional heteroatoms selected from N, O and S, and is optionally substituted with one or more substituents selected from R^6;

R^6 is:

1) $O_r(C=O)_sNR^aR^b$,
2) $(C=O)_rO_s$aryl,
3) $(C=O)_rO_s$-heterocyclyl,
4) halogen,
5) OH,
6) oxo,
7) $O(C_1\text{-}C_3)$perfluoroalkyl,
8) $(C_1\text{-}C_3)$perfluoroalkyl,
9) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl,
10) CHO,
11) CO_2H, or
12) CN,

wherein r and s are independently 0 or 1, and said alkyl, aryl, and heterocyclyl are optionally substituted with one or more substituents selected from R^d;

R^a and R^b are independently:

1) H,
2) $(C=O)_r(C_1\text{-}C_{10})$alkyl,
3) $S(O)_2R^c$,
4) $(C=O)_r$heterocyclyl,
5) $(C=O)_r$aryl, or

6) CO_2R^c,

wherein r is 0 or 1 and said alkyl, heterocyclyl, and aryl optionally substituted with one or more substituents selected from R^d, or

R^a and R^b are taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^d;

R^c is $(C_1\text{-}C_6)$alkyl, aryl, benzyl, or heterocyclyl;

R^d is:

1) $(C{=}O)_rO_s(C_1\text{-}C_{10})$alkyl, wherein r and s are independently 0 or 1, optionally substituted with up to three substituents selected from OH, $(C_1\text{-}C_6)$alkoxy, halogen, CN, oxo, $N(R^e)_2$ and $S(O)_2R^c$,
2) $(C{=}O)N(R^e)_2$,
3) $O_r(C_1\text{-}C_3)$perfluoroalkyl,
4) $(C_0\text{-}C_6)$alkylene-$S(O)_mR^c$, wherein m is 0, 1 or 2,
5) oxo,
6) OH,
7) halogen,
8) CN,
9) $(C_0\text{-}C_6)$alkylene-aryl, optionally substituted with up to three substituents selected from R^e,
10) $(C_0\text{-}C_6)$alkylene-heterocyclyl, optionally substituted with up to three substituents selected from R^e,
11) $(C_0\text{-}C_6)$alkylene-$N(R^e)_2$,
12) $C(O)R^c$,
13) CO_2R^c,
14) C(O)H, or
15) CO_2H; and

R^e is H, $(C_1\text{-}C_6)$alkyl, aryl, heterocyclyl or $S(O)_2R^c$.

2. (Original) The compound of Claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^1 is selected from:

1) H,
2) CN,
3) halogen,
4) OH,
5) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl, and
6) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl-$NR^aR^b$.

3. (Original) The compound of Claim 2 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^2 is selected from:

1) H,
2) CN,
3) OH
4) halogen,
5) phenyl, wherein said phenyl is optionally substituted with one or more substituents selected from R^6,
6) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl, and
7) $(C=O)_rO_s(C_1\text{-}C_{10})$alkyl-$NR^aR^b$.

4. (Original) The compound of Claim 3 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^4 is selected from:

1) H,
2) CN,
3) halogen,
4) $(C_1\text{-}C_6)$alkyl,
5) $(C_1\text{-}C_6)$perfluoroalkyl, and
6) $(C=O)_rO_s$heterocyclyl.

5. (Original) The compound of Claim 4 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R^1 is H; R^2 is CN or phenyl; R^3 is H; and R^4 is H or (C_1-C_6)alkyl.

6. (Original) A compound of Claim 1 selected from:
tert-butyl-4-({6-[(5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}oxy)piperidine-1-carboxylate;
2-{[6-(piperidin-4-yloxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
tert-butyl-4-({6-[5-phenyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}oxy)piperidine-1-carboxylate;
N-(5-phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)pyrimidin-4-amine;
tert-butyl-4-[({6-[5-cyano-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}oxy)methyl]-piperidine-1-carboxylate;
tert-butyl-4-[({6-[(5-phenyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}oxy)methyl]-piperidine-1-carboxylate;
N-(5-phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-ylmethoxy)pyrimidin-4-amine;
2-{[2-methyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
N-(5-phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)-2-methylpyrimidin-4-amine;
2-({2-methyl-6-[(3R)-pyrrolidin-3-yloxy]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-({2-methyl-6-[(3S)-pyrrolidin-3-yloxy]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-[2-methyl-6-{[1-(2-morpholin-4-ylethyl)piperidin-4-yl]oxy}pyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile;
2-[4-({6-[5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}oxy)piperidin-1-yl]-N-isopropylacetamide;
2-{[2-methyl-6-(3-morpholin-4-ylpropoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(2-piperidin-1-ylethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-({2-methyl-6-[(2-morpholin-4-ylethyl)amino]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-{[6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-({6-[(3-morpholin-4-ylpropyl)amino]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;

2-[(6-{[3-(1H-imidazol-1-yl)propyl]amino}-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile;
2-[(6-{[(1,1-dioxidotetrahyrothien-3-yl)methyl]amino}-2-methylpyrimidin-4-yl) amino]-1,3-thiazole-5-carbonitrile;
2-({6-[(1,4-dioxan-2-ylmethyl)amino]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-({6-[(3-morpholin-4-ylpropyl)amino]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-[-({6-[5-cyano-1,3-thiazol-2-ylamino]-2-methylpyrimidin-4-yl}amino)piperidin-1-yl]-N-isopropylacetamide;
tert-butyl-4-({6-[(5-cyano-1,3-thiazol-2-ylamino]-2-methylpyrimidin-4-yl}amino) piperidine-1-carboxylate;
2-{[2-methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
tert-butyl-4-({6-[(5-cyano-1,3-thiazol-2-yl)amino]methyl}-2-methylpyrimidin-4-yl}amino) piperidine-1-carboxylate;
2-({2-methyl-6-[(piperidin-4-ylmethyl)amino]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-{[5-methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]oxy}-1,3-thiazole-5-carbonitrile;
tert-butyl-2-[({6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}oxy) methyl]-morpholine-4-carboxylate;
2-{[2-methyl-6-(morpholin-2-ylmethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(tetrahydro-2-pyran-4-yloxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-{[2-isopropyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
2-({6-[(1,1-dioxidotetrahydrothien-3-yl)amino]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile;
2-{[2-methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
tert-butyl{4-[({6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}oxy) methyl]piperidin-1-yl}acetate;
{4-[({6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}oxy)methyl] piperidin-1-yl}acetic acid;
N-(tert-butyl)-2-{4-[({6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}oxy)methyl]piperidin-1-yl}acetamide;
2-({2-methyl-6-[(2-morpholin-4-ylethyl)thio]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile; and

2-{[6-(piperidin-4-ylthio)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile;
or a pharmaceutically acceptable salt or stereoisomer thereof.

7. (Currently amended) A compound according to Claim 1 which is 2-({2-methyl-6-[(3S)-pyrrolidin-3-yloxy]pyrimidin-4-yl}amino)-1,3-thiazole-5-carbonitrile



or a pharmaceutically acceptable salt or stereoisomer thereof.

8. (Currently amended) A compound according to Claim 1 which is:
N-(5-phenyl-1,3-thiazol-2-yl)-6-(piperidin-4-yloxy)pyrimidin-4-amine



or a pharmaceutically acceptable salt thereof.

9. (Currently amended) A compound according to Claim 1 which is:
2-{[2-methyl-6-(piperidin-4-yloxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile



or a pharmaceutically acceptable salt thereof.

10. (Currently amended) A compound according to Claim 1 which is:
2-{[2-methyl-6-(morpholin-2-ylmethoxy)pyrimidin-4-yl]amino}-1,3-thiazole-5-carbonitrile



or a pharmaceutically acceptable salt or stereoisomer thereof.

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

15. (Original) A method of treating or preventing cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1.

16. (Original) A method of treating or preventing cancer in accordance with Claim 15 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx, and lung.

17. (Cancelled)

18. (Cancelled)

19. (Original) A method of treating or preventing a disease in which angiogenesis is implicated, which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

20. (Original) A method in accordance with Claim 19 wherein the disease is an ocular disease.

21. (Original) A method of treating or preventing retinal vascularization which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of compound of Claim 1.

22. (Original) A method of treating or preventing diabetic retinopathy which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of compound of Claim 1.

23. (Original) A method of treating or preventing age-related macular degeneration which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Original) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,

4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) another angiogenesis inhibitor.

40. (Original) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) another angiogenesis inhibitor.

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Cancelled)

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (Cancelled)